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ABSTRACT 
NSCLC is the leading cause of cancer-related death worldwide. EGFR targeted therapy is 
used to inhibit the progress of NSCLC, but patients inevitably develop resistance to EGFR-
TKIs.  
The work presented in this thesis aimed at better understanding response and resistance 
mechanisms to EGFR-TKIs in NSCLC and to find novel biomarkers as well as drug targets 
or combination therapies for NSCLC.  
Paper I suggested a group of miRNAs with AAGUGC motif as oncomotif-miRNAs. Through 
the control of their target tumor suppressors, the oncomotif-miRNAs are part of the 
oncogenic signaling network that regulates NSCLC’s and other types of cancer’s cell 
proliferation.  
Paper II identified that BCL6, FGFR2, and JAK3 were upregulated after EGFR-TKI 
treatment. Moreover, BCL6 together with EGFR were confirmed to contribute to treatment 
escape. Dual targeting of BCL6 and EGFR could therefore be a potential combination 
therapy for treating NSCLC.  
Paper III reported that CDKN2A loss is associated with EGFR-TKIs sensitivity in EGFRwt 
NSCLC, and that BCL2L1 (encoding for BCL-xL) overexpression existed before EGFR-TKI 
treatment in a subset of EGFR-TKI responding cell lines. Additionally, EGFRwt/KRASwt, 
CDKN2A deleted NSCLC is sensitive to BCL-xL and EGFR dual inhibition, which could be 
a potential combination therapy for patients with this profile. These findings suggest that 
CDKN2A deletion can be used as a biomarker to select EGFRwt KRASwt patients for EGFR-
TKI based combination therapy.  
Paper IV identified the upregulation of AXL and GAS6, EMT, MAPK pathway reactivation, 
and AXL dependent CDK1 phosphorylation as potential resistance mechanisms of the third-
generation EGFR-TKIs.  
The work summarized in this thesis add new knowledge to understand the EGFR-TKI 
response and resistance mechanisms in NSCLC. From our work CDKN2A and oncomotif-
miRNA have been identified as interesting candidates that can be investigated for use as 
biomarkers in NSCLC. Moreover, we propose that BCL6 or BCL-xL inhibitors together with 
EGFR-TKIs should be further investigated as a combination therapy.  
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1 BACKGROUND 
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related 
death worldwide, which causes 1.8 million deaths per year (18.4% of all cancer deaths)1. Risk 
factors of developing lung cancer include cigarette smoke, secondhand smoke (passive 
smoking), radon, asbestos, diesel exhaust, and ionizing radiation exposure. Smoking is highly 
associated with lung cancer development, and are estimated to be the cause of 85-90% lung 
cancer cases2. Lung cancer can be classified into two broad histological subtypes based on the 
tumor cell appearance: non-small-cell lung cancer (NSCLC, accounting for 85% of the lung 
cancer cases) and small-cell lung cancer (SCLC, accounting for 15% of the cases)2.  
Compared with NSCLC, SCLC has some unique characteristics, including high lethality, 
rapid tumor growth, early and aggressive metastasis, and near widespread inactivation of 
TP53 and RB1 tumor suppressor genes3. In this thesis, the discussion will focus on NSCLC. 
1.1 LUNG CANCER EPIDEMIOLOGY  
Lung cancer incidence and mortality are usually highest in developed countries. Among 
males, lung cancer is the primary cause of cancer-related death in East Europe, West Asia, 
North Africa, East Asia (China, Japan, and South Korea), and Southeast Asia (Burma, 
Philippine, Indonesia). Especially in East Asia, the population incidence of lung cancer is 
more than 40 age-standardized rate (ASR) per 100,000 person per year4. Among females, 
lung cancer is still one of the leading causes of cancer-related death. Countries with the high 
incidence (> 35 ASR per 100,000 person per year) of lung cancer include United States of 
America, Europe (Hungary, Serbia, Greece, Belgium, Denmark, Poland, France, Bosnia), 
Turkey, China, and North Korea4. Although smoking is the most notable risk factor of lung 
cancer, 10-15% of non-smokers developed lung cancer5.  
1.2 CLASSIFICATION 
NSCLC is classified into three major histological types: adenocarcinoma (ADC, 50% of 
NSCLC), squamous cell carcinoma (SQCC, 40%), and large cell carcinoma (LCC, 10)2,6. 
ADC and SQCC are the predominant NSCLC subtypes2,6. ADC has glandular histology and 
it forms in glands that secrete mucus. It arises from the cells located along the alveolar wall or 
bronchiolar epithelium. ADC often express markers such as thyroid transcription factor 1 
(TTF1) that can be detected with immunohistochemistry6. SQCC develops in larger, more 
central airways, progresses through squamous differentiation, and has been associated with 
smoking. Markers frequently used to identify SQCC include SOX2, p63, cytokeratin 5 
(CK5), and cytokeratin 6 (CK6).  Cells of LCC do not have a squamous or glandular shape, 
or do not express ADC or SQCC markers6. Since 2003, the significant changes in lung cancer 
basic and clinical research field reveals that a more detailed histological classification of 
ADC is associated with patient prognosis and survival. In contrast, SQCC and LCC 
classification have largely remained the same. The 2015 WHO classification of lung tumors 
started to use the invasive statuses of ADC to further group the early-stage lung cancer. 
Early-stage lung cancer is split into three subtypes: adenocarcinoma in situ, minimally 
invasive adenocarcinoma, and invasive adenocarcinoma2.  Surgery is recommended for non-
invasive ADC, as the 5-year survival rate almost reaches 100%. Invasive ADC can be further 
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classified based on tumor growth type: lepidic, acinar, papillary, solid, and micropapillary.  
Prognosis of these invasive ADC subtypes rank from good to poor: lepidic ADC > acinar or 
papillary ADC > solid or micropapillary ADC.  In general, the aim of the exact 
histopathological classification for NSCLC is to guide the treatment and assess the prognosis 
of patients7,8.  
1.3 MUTATIONS IN NSCLC  
NSCLC is a group of diseases that has genetic and cellular heterogeneity. Common driver 
mutations that have been implicated to influence the oncogenesis of NSCLC have been 
reported in many studies, including EGFR mutation9–11, FGFR1/2 amplification or 
mutation12,13, ALK fusion14, MET amplification15, ROS1 fusion16–18, RET fusion19,20, ERBB2 
amplification or mutation21,22, KRAS mutation23,24,  BRAF mutation25–27, MEK1 mutation28, 
and CDKN2A deletion29–31. The NSCLC subtypes have different molecular profiles from 
each other. An overview on key oncogenes, and the main gene alterations along with FDA 
approved targeted drugs for NSCLC is summarized in Table 1.  
Gene Status Frequency (%)  FDA approved targeted drugs  
 ADC SQCC 
RTKs 
EGFR 
Amplification 6.8 6.8 
Gefitinib, Erlotinib, Afatinib, Osimertinib 
Mutation 20.2 3.2 
FGFR1 Amplification 2.1 17.6 
Erdafitinib, Pemigatinib FGFR2 Amplification 0.3 0.3 
FGFR2 Mutation 1.5 2.7 
ALK Fusion 1.7 N/A Alectinib, Crizotinib, Ceritinib 
MET Amplification 2.6 1.4 Crizotinib 
ROS1 Fusion 1.7 N/A Crizotinib 
ERBB2 
Amplification 2.5 2.6 
Trastuzumab, Neratinib, Lapatinib, Tucatinib 
Mutation 2.9 2.3 
RET Fusion 0.9 N/A Cabozantinib, Vandetanib 
DDR2 Mutation 2.7 2.4 Dasatinib 
PDGFRA Mutation 5.5 4.5 Sunitinib 
Signaling 
KRAS Mutation 29.1 1.3 N/A 
BRAF Mutation 6.6 3.7 Vemurafenib, Dabrafenib + Trametinib 
PIK3CA Mutation 5.7 12.8 Alpelisib 
MEK1 Mutation 1.5 1.1 Selumetinib 
Transcription factors 
SOX2 Amplification 1.6 43.9 N/A 
MYC Amplification 8 8.4 N/A 
Cell cycle 
CDKN2A Mutation 4.8 15.3 N/A 
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Deletion 13.9 27 
CDKN2B Deletion 13.4 26.8 N/A 
Tumor suppressor 
TP53 Mutation 50.3 83 N/A 
PTEN Mutation 2.1 9.4 N/A 
Table 1:  Overview of common gene alterations in lung ADC and SQCC. This table shows an overview on 
key oncogenes, and the main gene alterations along with FDA approved targeted drugs for NSCLC. The 
abbreviations used in this table: EGFR, epidermal growth factor receptor;  FGFR1, fibroblast growth factor 
receptor 1; FGFR2, fibroblast growth factor receptor 2; ALK, anaplastic lymphoma kinase; MET: MET proto-
oncogene;  ROS1:  ROS proto-oncogene; ERBB2: Erb-B2 receptor tyrosine kinase 2; RET: Ret proto-oncogene;  
DDR2: discoidin domain receptor tyrosine kinase 2; PDGFRA, platelet-derived growth factor receptor-α; KRAS: 
KRAS proto-oncogene; BRAF: B-Raf proto-oncogene; PIK3CA: PI3K catalytic subunit-α; MAP2K1: mitogen-
activated protein kinase kinase 1; SOX2, SRY-box 2 transcription factor 2; MYC: MYC proto-oncogene; 
CDKN2A, cyclin-dependent kinase inhibitor 2A; CDKN2B, cyclin dependent kinase inhibitor 2B; TP53: tumor 
protein P53; PTEN: phosphatase and tensin homolog. The frequency data from the combined study was 
collected using cBioPortal32,33. Lung ADC frequency data are from the combination of 7 studies (Broad, Cell 
2012; MSKCC, Science 2015; TCGA, Firehose Legacy; TCGA, Nature 2014; TCGA, PanCancer Atlas; TSP, 
Nature 2008; MSKCC, Cancer Discov 2017). Lung SQCC frequency data are from the combination of 3 studies 
(TCGA, Firehose Legacy; TCGA, Nature 2012; TCGA, PanCancer Atlas).  Data in this table partially taken 
from Chen et al., 20146.  
The rapid development of high throughput sequencing techniques dramatically changed the 
way of describing NSCLC at the molecular level. Previously, The Cancer Genome Atlas 
(TCGA) research group released their molecular profiling results of lung ADC and lung 
SQCC31,34, which included a thorough analysis of the driver oncogenes and mutations. TCGA 
identified high rates of somatic mutations and listed 18 significant genetic mutations in lung 
ADC34. Alterations in key pathways of lung ADC are visualized in Fig. 1.  
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Figure 1:  Altered pathways in lung ADC.  Alterations in key pathways of lung ADC such as Receptor 
tyrosine kinase (RTK) signaling, mTOR signaling, cell proliferation, and cell cycle progression.  Reprinted 
under the Creative Commons Attribution 4.0 International License, http://creativecommons.org/licenses/by/4.0/ 
from Nature 511, 543-550(2014). The Cancer Genome Atlas Research Network. Comprehensive molecular 
profiling of lung adenocarcinoma. 
TCGA reported 10 significantly mutated gene mutation in SQCC. Pathways that were 
frequently altered in lung SQCC were related to oxidative stress response and squamous cell 
differentiation. The paper also provided frequently altered pathways found in SQCC, as 
visualized in Fig. 2.  
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Figure 2:   Altered pathways in lung SQCC.  The frequently alterated pathways are showed. Left part is 
oxidative stress response pathway and the right is squamous differentiation pathway. Reprinted under the 
Creative Commons Attribution 4.0 International License, http://creativecommons.org/licenses/by/4.0/ from 
Nature 489, 519-525(2012). The Cancer Genome Atlas Research Network. Comprehensive genomic 
characterization of squamous cell lung cancers. 
1.4 SCREENING 
The aim of lung cancer screening is to detect the tumor at an early-stage since it is 
challenging to get curative treatment for advanced-stage tumors. The National Lung Cancer 
Screening Trial in the United States proposed that annual screening with low-dose computed 
tomography could potentially reduce lung cancer mortality by 20% or more in high-risk 
groups35. China did a similar screening experiment in a rural area since 2009 to determine 
proper screening guidelines for Chinese citizens. Both countries issued guidelines for lung 
cancer screening that recommend screening healthy patients with certain risk factors, which 
are quite similar: older age group and history of smoking.  The National Comprehensive 
Cancer Network Clinical Practice Guidelines in Oncology for lung cancer screening (Version 
3.2018) set the risk group criteria to be aged > 50 years, at least 20 pack per year smoking 
history, either quit smoking < 15 years or has additional risk factors to develop lung cancer36. 
The Chinese national lung cancer screening guideline (2018 version) has similar criteria, 
except a lifted smoke cessation bar to < 5 years and some added high-risk factors (e.g. long 
history with indoor coal smoke) for cities with high lung cancer incidence37. Moreover, 
patients with a specific size of lung nodules need to be further examined and undergo further 
diagnostics36,37.  
1.5 DIAGNOSIS  
Typical symptoms of NSCLC include cough (> 50% of cases), hemoptysis (25-40% of the 
cases), chest pain (or other parts of body pain, due to distant metastasis), dyspnea, fever, and 
wheeze. Suspected patients are recommended to undergo various examinations, including 
taking tissue biopsy for NSCLC diagnosis and further classification. Regular examinations 
include serologic testing of NSCLC diagnostic markers (increased level of carcinoembryonic 
antigen, cytokeratin fragment 21-1, squamous cell carcinoma antigen), imaging examination 
(e.g., X-ray, computed tomography, magnetic resonance imaging, and positron emission 
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tomography-computed tomography), endoscopy examination, and histopathological 
examination. All the examinations contribute to the tumor, node, and metastasis  (TNM) 
classification of NSCLC2,38,39. When tissue biopsy is available, an immunohistochemical 
examination can be performed for diagnosis, using biomarkers (TTF-1, p63, CK5, and CK6) 
to distinguish between ADC and SQCC38. Leftover tissue can then be used for molecular 
testing (e.g. EGFR mutation, ALK fusion gene, and ROS1 fusion gene detection for 
advanced-stage NSCLC) to decide therapeutic stratagy2,38,40. 
1.6 TREATMENT 
Essential information to determine an appropriate treatment towards individual NSCLC 
patients is the tumor’s histological classification (chapter 1.2), staging, and molecular 
classification.   
Treatment options for NSCLC are mainly surgery, chemotherapy, radiotherapy, targeted 
therapy, and immunotherapy. The exception being that immunotherapy is not yet available 
for LCC. LCC occurs rarely but is more malignant and metastasizes faster than other types of 
NSCLC. SQCC grows slower than other types of NSCLC. Therefore, surgery is more 
suitable to treat SQCC at an early stage. 
The staging classification is useful to determine if the tumor is removable by surgery or not. 
The staging (clinical, or pathological) of NSCLC classifies into 0, I, II, III, IV, based on the 
size, location, and metastasis condition of the tumor. The only difference between clinical 
and pathological staging is that the former is based on the test results (e.g. computed 
tomography scan) before surgery, and the latter is based on the conclusion from tissue taken 
during surgery.  In general, tumor in stage 0/I/II is surgically removable. In contrast, surgery 
is not an option for patients with tumors in stage III/IV with metastases to lymph nodes or 
even to other organs.  
The survival rate of NSCLC patients is highly related to the clinical stage (size and location 
of the tumor); in short, the more tumor metastases, the lower the survival rate is. The 5-year 
survival rate drops from 54% to 2-15% in NSCLC when the tumor develops from stage I to 
III/IV41,42. The clinical management of each patient differs depending on the tumor 
characteristics. Detecting the tumor in early-stage is vital for patient survival and increases 
the applicability of curative treatment (e.g. surgery). However, the reality is that many 
NSCLC patients are first diagnosed at an advanced stage when the disease is usually 
incurable.  
In the past decade, breakthroughs of molecular diagnostics have improved the clinical 
management of NSCLC dramatically, as patients can be tested and profiled for the presence 
of well-known driver mutations. Some of the well-known driver mutations have been used as 
predictive treatment-biomarkers to select patients who will respond to treatment in NSCLC 
clinical practice. Successful examples include activating mutations in EGFR, ALK 
chromosomal translocation and fusion, and ROS1 chromosomal translocation and fusion. As 
drug targets, these mutations have been used for designing targeted cancer drugs (e.g. 
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gefitinib). Targeted drugs are selected to treat patients who carry specific mutations and for 
NSCLC, one of the well-known targets is EGFR activating mutation43. 
1.7 EGFR TARGETED THERAPY  
1.7.1 EGFR  
The EGFR gene is located on chromosome 7, coding for a matured 1186-residue, 170-kDa   
transmembrane protein EGFR. From the N- to C-terminal, EGFR comprises an extracellular 
domain that controls the ligand binding, a transmembrane and juxtamembrane segment, an 
intracellular tyrosine kinase domain,  and a C-terminal tail domain44.  It belongs to the ERBB 
family, which includes four members with similar molecular structures (EGFR/ERBB1, 
ERBB2(HER2), ERBB3, ERBB4). Upon binding with its ligands (e.g. EGF, TGFa) EGFR 
dimerizes with another EGFR or ERBB and autophosphorylates its tyrosine kinase domain.  
The activated EGFR can interact with adaptor molecules and regulates the intracellular 
signaling through RAS-RAF-MEK-MAPK, PI3K-PTEN-AKT, and JAK-STAT pathways. In 
this way, the EGFR downstream signaling controls cell proliferation, survival, and 
apoptosis45,46.   
The studies of EGFR and its pathway began with pioneer work initiated by 1986’s Nobel 
prize winner Stanley Cohen. In the 1960s, he isolated the epidermal growth factor (EGF) and 
named it based on the observation that it stimulates the epidermal cell growth in vitro and in 
vivo47–49. In 1977, Manjusri Das and colleagues identified a cell surface receptor for EGF in 
mouse cells50. In the early 1980s, Cohen reported that in A431 cells, EGF binds to its 
receptor, a 170 KDa membrane protein named EGF receptor (EGFR)51,52. Later on, Ushiro 
and Cohen discovered that the EGF-enhanced phosphorylation reaction in EGFR mainly 
happened on its tyrosine residues, which suggested that the EGF signaling involved protein 
tyrosine kinase activity53. In the mid of 1980s there were studies that reported the sequencing 
of the EGFR gene, and that the EGFR gene was amplified and rearranged in cancers54–61. The 
expression level of EGFR in normal human fibroblasts is estimated to be 40,000-100,000 
receptors per cell, whereas in the EGFR overexpressed epidermoid carcinoma cell line A431 
there was 2*106 receptors per cell58,59. In the late 1980s, scientists suggested that the EGFR 
status could be used as a predictor of tumor size, relapse-free survival, and patient prognosis 
in breast cancer60. EGFR overexpression associates with poor patient prognostics and 
progression of many cancers, including head and neck, ovarian, cervical, bladder, breast 
cancer, vulva cancer, and NSCLC59,61. EGFR was the first among the RTK family to be 
linked with cancer when the receptor expression level is abnormal. 
Previous meta-analysis reported that the EGFR mutation frequency in NSCLC patient is 
32.3%, and among the Asian patients, mutation frequency was significantly higher (38.8%) 
than Caucasian patients (17.4%)62.  Other factors that associate with high EGFR mutation 
include smoking status, histology and gender62. EGFR activating mutations frequently occur 
in kinase-coding regions (exon 18-21), clustered around the ATP-binding pocket of EGFR 
tyrosine kinase domain63. Reported EGFR activating mutations include exon 19 deletions, 
point mutation exon 18 G719X (X indicates A or C), and exon 21 L858R9,10. In total, exon 21 
L858R and exon 19 deletions account for ~80-90% of EGFR tyrosine kinase mutations in 
NSCLC (data from COSMIC cancer browser using their NSCLC samples64). The activating 
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mutation results in the constant activation of EGFR kinase activity, which results in constant 
activation of the downstream signaling and uncontrolled cancer cell proliferation and 
survival65. EGFR is therefore a prominent drug target for NSCLC patients with EGFR 
activating mutations.   
1.7.2 EGFR-TKIs 
Developing the EGFR targeted drugs includes two different approaches. One is to design an 
antibody that targets the EGFR extracellular domain, while the other is to design a small-
molecular EGFR tyrosine kinase inhibitor (TKI) that targets intracellular tyrosine kinase 
domain of EGFR. This section will focus on EGFR-TKIs. Currently, three generations of 
EGFR-TKIs for treating NSCLC are approved by FDA for treating NSCLC, and the fourth 
generation of EGFR-TKIs are undergoing the drug development process. 
First-generation of FDA approved EGFR-TKIs are gefitinib (Iressaâ,	 AstraZeneca) and 
erlotinib (Tarcevaâ,	 Genetech/Roche). Both gefitinib and erlotinib are reversible small 
molecular inhibitors based on a 4-anilinoquinazoline scaffold, and are designed to target exon 
19 deletion or L858R mutant EGFR. They share similar binding mechanisms: inhibiting 
kinase function by mimicking the ATP molecule to competitively bind to the ATP binding 
pocket of the EGFR TK domain, hence reduces the downstream signaling that regulates cell 
proliferation and survival. During the clinical trials, researchers noticed that patients with 
EGFR L858R mutation in exon 21 or deletions in exon 19 responded well towards gefitinib 
or erlotinib9,10,66. Yun and colleagues reported that the potency of gefitinib to EGFRL858R is 
100 times fold higher than wild type EGFR, which explains why patients carrying EGFRL858R 
or EGFR exon19 in-frame deletion respond to the first generation of EGFR-TKIs67. 
Unfortunately, the first-generation EGFR-TKIs brought epithelial toxicity as a side effect due 
to the inhibition of wild type EGFR in the skin and GI tract. Later on, researchers discovered 
that not all NSCLC patients could benefit from the first-generation of EGFR-TKIs because of 
intrinsic and acquired resistances (see 1.8.2). For instance, EGFR T790M mutation makes the 
tumor resistant to first generation EGFR-TKIs68–70.  
The second-generation of EGFR-TKIs approved by the FDA includes afatinib (Gilotrifâ, 
Boehringer Ingelheim) and dacomitinib (Vizimproâ, Pfizer). Both drugs share a 4-
anilinoquinazoline structure and are irreversible pan-ERBB TKIs (EGFR, ERBB2, ERBB4). 
They are not only ATP mimics that can covalently bind to Cys797 of EGFR, but can also 
irreversibly bind to other ERBB family member receptors and block their enzyme activity. 
For instance afatinib, it binds with wild type EGFR through forming a hydrogen bond 
between  Met793 and the quinazoline core of afatinib, as well as a covalent bond between 
Cys797 and the acrylamide group of afatinib71. Moreover, it inhibits other ERBB family 
members by forming covalent bonds also with these kinases71. The irreversible binding of 
afatinib to ERBB2 inactivates the preferred dimerization of ERBB2 with EGFR and hence 
prevent downstream signaling. Although the second-generation EGFR-TKIs showed 
potential to overcome T790M resistance by irreversible covalent binding with the target 
kinase, the drug efficacy in patients was insufficient, as demonstrated by the LUX-Lung 1 
clinical trial result of 7% of responding rate and 3.3 months of progression-free survival72. 
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Irreversible binding towards EGFRwt caused increased toxicity, which further limited the 
clinically achievable concentration due to side effects such as skin rash and diarrhea.  
The design of the third-generation of EGFR-TKIs considered several aspects to be able to 
target EGFRT790M more successfully. The drug candidates needed to be mutant-specific in 
order to avoid binding to EGFRwt and hence lessen side effects. The drug candidates also 
needed to have a substituent to bind with Cys797 and avoid steric conflict with Met790 in 
order to stabilize binding73. The FDA approved drug osimertinib (Tagrissoâ, AstraZeneca) 
managed to satisfy the three mentioned aspects73. Osimertinib is a pyrimidine-based EGFR-
TKI, which contains an acrylamide group for Cys797 binding. Cross and colleagues showed 
that the binding of osimertinib to EGFRT790M took place via two hydrogen bonds to the hinge 
region (Met793), and a covalent bond between the acrylamide group of osimertinib and 
Cys79773. Osimertinib selectively and irreversibly target sensitizing mutants of EGFR 
(EGFRL858R and EGFR ex19del) as well as the resistance mutant EGFRT790M. The affinity of 
osimertinib to EGFRwt is much lower compared to any of the following: T790M, L858R, 
and ex19del73. Less binding to EGFRwt reduced the toxicity of osimertinib, supported by the 
fact that the skin rash occurred in 58% of patients with osimertinib treatment compared to 
78% with first-generation of EGFR-TKIs74. Osimertinib showed better progression free 
survival (PFS) of 9.6 months in EGFRT790M harboring patients and significantly reduced 
toxicity due to lower unspecific binding to wild type EGFR75. Later on, EGFRC797S was 
identified as a leading acquired resistance mechanism to third-generation of EGFR-TKIs, 
which guided the development of fourth-generation EGFR-TKIs76,77. 
Currently, no fourth-generation of EGFR-TKIs are approved. The design of fourth-generation 
EGFR-TKIs was based on the acquired mutation EGFRC797S after treatment with third-
generation EGFR-TKIs. The first fourth-generation EGFR-TKIs reported was EAI04578. 
Different from the previous three generations of EGFR-TKIs that target the ATP site of 
EGFR, it is an allosteric, non-ATP competitive inhibitor with high potency and selectivity for 
EGFRT790M/EGFRL858R mutation.  When combined with EGFR targeting antibody cetuximab, 
EAI045 was able to induce tumor regression in mouse models with EGFRL858R/T790M/C797S 
triple mutation78. Fig.3 below shows a history of EGFR-TKI related discoveries and FDA 
approvals. The next section will focus on introducing the resistance mechanisms of EGFR-
TKIs. 
 
 10 
 
Figure 3: A history of EGFR targeted therapy and FDA approved drugs for NSCLC.  The left side of 
the timeline listed the relevant FDA approvals of EGFR-TKIs. The right side of the timeline listed the critical 
scientific discoveries regarding EGFR targeted therapy. All the events have been placed chronologically, with 
the most recent events closer to the top. R*: resistance mechanisms to EGFR-TKIs.  Mut.: EGFR activating 
mutations (exon 19 deletion or exon 21 L858R mutation). 
1.8 MECHANISMS OF RESISTANCE TO EGFR-TKIS 
EGFR targeted therapy using EGFR-TKIs improves the prognosis of NSCLC patients, but 
the response is usually temporary, patients inevitably develop resistance to EGFR-TKIs. The 
resistance mechanisms to EGFR-TKIs can be classified into intrinsic resistance and acquired 
resistance mechanisms. These resistance mechanisms of EGFR-TKIs are summarized in 
Fig.4.  
  11 
 
Figure 4: Resistance mechanisms towards EGFR-TKIs in NSCLC. The resistance mechanisms towards 
EGFR-TKIs include primary resistance, second-site mutations on EGFR, failure in EGFR downregulations and 
bypass signaling pathways. Abbreviations: GAS6: growth arrest specific 6; AXL: AXL receptor tyrosine kinase; 
HGF: hepatocyte growth factor; MET: hepatocyte growth factor receptor; ERBB3: receptor tyrosine kinase erb-
B3; mTOR: mammalian target of rapamycin; PTEN: phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and 
dual-specificity protein phosphatase PTEN. Adapted from Rotow J. 201779.  
1.8.1 Intrinsic resistance mechanisms 
Intrinsic resistance to EGFR-TKIs is defined as immediate inefficacy when receiving EGFR-
TKI treatment. 
1.8.1.1 Resistant EGFR mutations 
The most frequently observed intrinsic EGFR-TKI resistant mutation is exon 20 insertion, 
which accounts for 4-10% of EGFR mutation80,81. Wu and colleagues first reported the 
association of inadequate gefitinib response with EGFR exon 20 deletion in 200880. ~90% of 
the exon 20 insertions lie near the end of the C-helix between amino acid 768-774, with 1-4 
amino acids82. The crystal structure of EGFR with an exon 20 insertion shows that the 
insertion sits at the end of C-helix to lock the helix in its activating position and blocks the 
conformational change that is required for EGFR-inactivation. In this manner, the activation 
of the EGFR mutant can no longer be inhibited by EGFR-TKIs81.  Exon 20 insertion 
mutations are commonly observed in Asian non-smoker patients with adenocarcinoma 
histology83.  
Another intrinsic resistance mutation on the EGFR target is T790M mutation. EGFRT790M is 
occasionally detected in germline and somatic cells of patients even before EGFR-TKI 
treatment has been prescribed. For instance, germline T790M mutation accounts for 0.54% of 
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never-smoker patients84. In an East Asian cohort, patients who carried T790M mutation 
before TKI treatment had been received were associated with a shorter PFS than those with 
wild type EGFR85. The EGFR T790M mutation can also be an acquired resistance mutation 
and is more frequently reported as such. It is therefore also explained in the context of an 
acquired resistance mechanism in section 1.8.2.1. 
1.8.1.2 EGFR-independent resistance mutations 
Intrinsic resistance can be induced by molecular or genetic alterations that are independent 
from EGFR mutations, but provide a similar uncontrolled downstream pathway activation. 
These alterations can be referred to as EGFR-independent resistance mechanisms.  
Mutations affecting EGFR downstream signaling are EGFR-independent resistance 
mechanisms, such as PTEN deletion and PIK3CA mutation, which continuously activates the 
PI3K/AKT pathway regardless of EGFR activation status86,87. Bypass signaling such as HGF 
overexpression and ALK rearrangement were also reported as intrinsic resistance 
mechanisms to EGFR-TKIs, which also are EGFR-independent resistance mutations14,88,89. 
Similar intrinsic resistance mechanisms were identified to the third-generation of EGFR-TKI 
drug osimertinib. For example, it was reported that AXL receptor tyrosine kinase (AXL) 
interacts with EGFR and ERBB3 to maintain cell survival and induce the osimertinib 
resistance90. In addition, ERBB2 amplification, MET amplification or SCLC transformation 
were all suggested to be potential intrinsic resistance mechanisms to osimertinib91,92.  
1.8.2 Acquired resistance mechanisms 
Acquired resistance occurs in tumors that initially respond to therapy but later on continue to 
progress.   
1.8.2.1 Second-site mutation on EGFR  
The most common acquired resistance mechanism of EGFR-TKIs is the T790M mutation, 
observed in ~50% of NSCLC patients with resistance to EGFR-TKIs93. T790 is a gatekeeper 
residue of EGFR located in the ATP binding pocket. It controls the entrance of EGFR-TKIs 
to the ATP binding pocket. When the T790M mutation occurs, the ATP affinity to EGFR 
increases, and binding ability of EGFR towards first-generation EGFR-TKIs reduces94. The 
increased ATP affinity to EGFR leads to the kinase phosphorylation, hence activates the 
downstream pathways to promote tumor progression. Other less reported secondary 
mutations on EGFR include D761Y on exon 19, L747S on exon 19, and T854A on exon 
2195–97.  
Unsurprisingly, the resistance to third-generation of EGFR-TKIs involves a second-site 
mutation. EGFR C797S mutation is a common third-generation EGFR-TKI resistance 
mechanism in patients with resistance to osimertinib76,98,99. Cys797 is located at the ATP 
binding site and the C797S mutation leads to covalent bond loss between EGFR and third-
generation EGFR-TKIs. Other rare reported resistance mutations to third-generation of 
EGFR-TKIs include C797G, G796X(R/S), and L792H100,101.   
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1.8.2.2 Aberrant EGFR downstream signaling 
The uncontrolled activation of EGFR downstream signaling can also be caused by acquired 
resistance to EGFR-TKIs.  In RAS / MAPK pathway, BRAF V600E mutation is a common 
acquired resistance mechanism that was observed following treatment with any of the three 
generations of EGFR-TKIs25,102,103. BRAF V600E mutant induces activation of BRAF, hence 
activates MEK-ERK. The reactivation of MAPK pathway is then independent from EGFR 
activation and results in lack of response to EGFR inhibition. ERK2 amplification, was also 
reported as a third-generation EGFR-TKI resistance mechanism by also reactivating the 
MAPK pathway independent of EGFR104. In the PI3K/AKT pathway, PI3KCA mutation or 
PTEN loss was reported to induce EGFR-TKI resistance and are suggested to be able to 
predict the poor response to EGFR-TKI in NSCLC patients86,105,106.  
1.8.2.3 Activation of bypass signaling pathways  
The EGFR-TKI resistance can be mediated by the activation of bypass signaling pathways 
that are independent of EGFR. Many of the bypass signaling are linked to the activity of other 
RTK family members. For instance, the amplification of RTK family member MET, was 
detected in 5-22% of patients with acquired resistance to first-generation of EGFR-
TKIs15,107,108. Once activated by its ligand HGF, MET activates ERBB3 tyrosine 
phosphorylation, and subsequently PI3K/AKT pathway to regulate cell proliferation and 
survival. The whole process is independent from EGFR activation15. The overexpression of 
HGF could also induce resistance via HGF mediated MET activation to restore the PI3K/Akt 
pathway. HGF overexpression was detected in 61% of patients with EGFR-TKI acquired 
resistance108.  Other overexpressed RTKs or their ligands such as ERBB2, AXL,  and GAS6, 
were reported to decrease sensitivity towards osimertinib, which confirmed its capacity to 
induce acquired resistance to EGFR-TKIs91,109–112. In general, activation of other RTK family 
members regulates downstream PI3K or MAPK signaling to promote cell proliferation and 
survival independent of EGFR activation status. 
1.8.3 Strategies to overcome EGFR-TKI resistance 
To overcome the resistance driven by EGFR mutations, the primary choice is to use 
appropriate EGFR targeting drugs. Resistance related to EGFR T790M mutation can be 
circumvented with osimertinib treatment. When it comes to EGFR exon 20 insertion 
mutation, it is possible to try Poziotinib, a covalent, irreversible EGFR/ERBB2 inhibitor that 
was reported to be 65 times more potent in inhibiting cell lines with EGFR exon 20 insertion 
than those harboring the EGFR T790M mutation. The initial reported response rate to 
poziotinib is 64% in NSCLC patients with EGFR exon 20 insertion (ongoing clinical trial 
NCT03066206)113.  
To overcome the resistance driven by EGFR-independent mechanisms, a suitable 
combination therapy using EGFR-TKI and other targeted drugs could lead to a good 
treatment outcome. Take tumors with ERBB2 amplification as an example, although there 
still being no approved combination therapy for EGFR and ERBB2 dual inhibition in 
NSCLC, approved targeted drugs for ERBB2 (trastuzumab, lapatinib, and pertuzumab) are 
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available for clinical trials. Another example is MET amplification. A clinical trial 
(NCT02468661) that combines erlotinib and FDA approved MET inhibitor capmatinib, has 
recently been finalized although no result published yet. Similar combination strategy can be 
investigated in other bypass signaling mechanisms such as BRAF mutation and KRAS 
mutation.  
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2 THE PRESENT WORK 
2.1 AIMS 
The general aim of the thesis was to investigate the response and resistance mechanisms of 
EGFR-TKIs in NSCLC, discover predictive biomarkers for drug response, and find novel 
drug targets to improve the current NSCLC therapy. Consistently throughout the work 
presented in this thesis, -omics methods (see 2.2.1 and 2.2.2) have been central in our 
investigations. 
The specific aims for each paper were as following: 
• Paper I: To identify and explore the oncogenic microRNAs (miRNA) function in 
NSCLC in relation to EGFR-TKI response and cellular signalling  
• Paper II: To explore the immediate adaptive response to EGFR inhibition and find 
drug targets for EGFR-TKI combination therapy in NSCLC 
• Paper III: To find novel biomarkers and new drug targets for EGFR-TKI combination 
therapy in NSCLC with wild type EGFR 
• Paper IV: To explore the resistance mechanisms of third-generation EGFR-TKIs in 
EGFR mutated NSCLC 
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2.2 METHODS 
Introduction to the main experimental and data analysis methods used in this thesis are 
summarized below.  
2.2.1 RNA sequencing and data analysis 
A transcriptomics study's focus is to identify and quantify mRNAs, but sometimes also other 
species of transcripts such as long non-coding RNAs or miRNAs. Classical technologies 
include hybridization-based or sequencing-based methods. Sequencing-based methods 
directly determine the cDNA sequence by tag-based Sanger sequencing of cDNA libraries. 
This includes the first-generation high throughput sequencing (commonly referred to as 
Sanger dideoxy sequencing, the automated Sanger method). First-generation sequencing 
generates sequences length of 600-1000 bases, and a standard run yields 100,000 bases.  
RNA sequencing methods are derived from next-generation sequencing (NGS) technology 
that is performed in a massively parallel manner (can consist of 6 billion sequencing reactions 
in a single run). A single run of NGS can generate 600 billion bases of sequence data114. As a 
comparison, the total human genome is about 3 billion base pairs. 
A typical workflow of an RNA sequencing (RNA-seq) experiment includes isolation of 
RNAs, quality control of RNAs, library construction, high-throughput sequencing, data 
processing, and data analysis. Depending on the material and the type of RNA, the selection 
of RNA isolation methods varies. For instance, commercially available products like RNeasy 
(Qiagen) can be used to isolate mRNA from cells or tissue samples. However, small RNAs 
(such as miRNA, siRNA, or small nuclear RNA) require methods with specialized RNA-
isolation columns that enrich for small RNAs (10-200 nucleotides). Before converting RNAs 
to a cDNA library used in sequencing, a quality check is performed on the RNA samples to 
check for degradation, purity, and quantity. In the next step, library preparation of RNAs to 
cDNAs is performed because RNA is more labile than DNA and hence not suitable for direct 
sequencing. The cDNA library should be representative of the original RNA sample.  
When the cDNA library is created, it can be used in a sequencing platform such as Illumina 
or SOLID (Applied Biosystems), among others. Depending on the platform, the tagging 
methods of cDNA molecules vary, for instance, Illumina ligates sequencing adaptors to 
targeted DNA molecules, and SOLID (Applied Biosystems) uses magnetic beads to tag 
DNA. After the sequencing step, the reads can be obtained. Quality control steps and pre-
processing of the sequencing data is also required to prevent possible problems for mapping 
to reference genomes later. Unprocessed sequences can, for example, contain low confidence 
bases or untrimmed adaptors (for Illumina data). Those problems can be solved by the 
FastQC program115. Data analysis begins after obtaining the reads from sequencers. The 
RNA-sequencing data can be used to explore multiple questions such as differential 
expression, splice variant expression, and novel fusion genes. For differential expression 
analysis, a general workflow could be as follows:  First, the raw data from the sequencer is 
pre-processed and aligned to a reference genome. Here the reads should be appointed to 
annotated genes or transcripts. Once genes or transcript models are generated, the sequencing 
depth is normalized across the samples. Then the expression levels of each transcript are 
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calculated. Commonly used expression units are “reads per kilobase per million mapped 
reads” (RPKM), “fragments per kilobase of transcripts per million fragments mapped” 
(FPKM), and “transcripts per kilobase million” (TPM). From here, the gene expression 
across experimental groups can be compared with the help of statistics116.  
Paper I/III performed standard RNA sequencing. Total RNA was extracted, quality checked, 
and progressed to RNA library preparation. The Sequencing was performed by HiSeq2500. 
FPKM values for genes and transcripts were reported after removing missing values. Paper 
II/III  performed differential expression analysis on total normalized read count values using 
DESeq2 R package117.  
2.2.2 MS-based Proteomics and data analysis  
The term proteomics was first introduced as ‘the protein complement’ of the genome in 
1990s and referred to the identification and sometimes quantification of all proteins present in 
an organism’s cell or organism’s cellular sub-compartment118. Proteomics strategies include 
bottom-up, middle-down, and top-down, which refer to the analysis of small peptides, large 
peptides (resulting from limited digestion or more selective protease), or whole proteins. 
Recent advances over the past decade in mass spectrometry (MS) have enabled the 
characterization of the proteome.  
To get a representative proteome, cell, or tissue lysis steps must ensure complete 
solubilization of proteins. This step usually needs optimization to be compatible with MS 
analysis. For example, when extracting membrane proteins, many protocols require 
solubilization based on detergents that interfere with the MS analysis and such detergents 
need to be replaced. Proteins are digested into peptides before the MS analysis. After 
enzyme digestion, the abundance of different peptides can span more than 7 orders of 
magnitude, making it difficult to identify low abundant peptides. In many cases, peptide 
pre-fractionation steps are applied before LC-MS analysis to reduce the sample complexity. 
Pre-fractionation methods available can separate peptides according to e.g., charge, 
hydrophobicity, or isoelectric point.  A recently published method called HiRIEF (high-
resolution isoelectric focusing) describes a solution to reduce sample complexity119. In this 
method, peptide mixtures are separated by isoelectric focusing (IEF), using immobilized pH 
gradient (IPG) gel strips. Typically, every sample is fractionated into 72 largely non-
overlapping fractions of peptides that are then analyzed individually by mass spectrometry, 
resulting in dramatically increased analytical depth. Mass spectrometry (MS) is an 
analytical method to ionize molecules such that they become gaseous and charged, enabling 
them to travel towards a detector. On the path to the detector, the ionized particles are 
accelerated by a magnetic field, whereby ions are separated according to their mass-to-
charge (m/z) ratios by the time they reach the detector. Traditionally, the ionization 
techniques generate high amount of heat. This causes proteins and larger peptides to 
fragment before ionizing and becoming gaseous, which alters the chemical composition and 
hence makes it impossible to derive the protein’s chemical composition or identity. A 
milestone of MS applications in protein chemistry, however, solved this with the 
introduction of soft-ionization techniques. This enabled proteins and larger peptides to 
become enclosed in aerosolized droplets (e.g. electrospray ionization) or matrix-media (e.g. 
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Matrix-assisted laser desorption/ionization) carrying a charge resulting in no decomposition 
in the ionization process such that they could be accelerated intact towards the detector.  
A typical shotgun (bottom-up) proteomics workflow looks as follows: All proteins from 
samples of interest (such as cells or tissues) are extracted and digested with one or several 
proteases (such as trypsin alone or combined with Lys-C) to generate a set of peptides. 
Depending on research question and sample, enrichment (for a specific set of proteins or 
peptides), labelling, and fractionation steps can be introduced to enhance detection, 
identification, and quantification. The peptides are then separated by liquid chromatography 
(LC), ionized by electrospray ionization, and analyzed by mass spectrometry. Multiple 
peptide ions entering the MS at the same time are analyzed with respect to their mass to 
charge ratio (m/z), resulting in an MS1 spectrum. In parallel, selected peptide ions are 
isolated, fragmented, and analyzed again to generate a fragment spectrum (MS2 or MS/MS) 
containing m/z information related to the different fragments from the selected peptide. The 
peptide and peptide fragment mass information generated in MS1 and MS2 steps of the 
analysis are then used to identify peptides through database matching towards a database 
containing all theoretical peptides from the organism under investigation. Through the 
identified peptides, the protein identifications are then inferred. The output of a proteomics 
analysis is commonly a list of identified proteins and peptides with related quantitative 
information. This data usually needs to be cleaned up and pre-processed before performing 
any statistical analysis and biological interpretation. This step includes removing missing 
values and outliers in the dataset as well as normalizing the data.  After this step, statistical 
analysis is applied to identify a subset of proteins that differ between sample groups in the 
experiment. More importantly, the data may need to be cross-referenced with other -omics 
data (e.g. transcriptomics) for context. Various bioinformatics tools are available for 
enrichment, pathway, and network analysis. As examples, Gene Ontology (GO) enrichment 
analysis, and Gene Set Enrichment Analysis (GSEA) provides methods to highlight genes 
or pathways based on their previous annotations and reveals differentially regulated 
biological pathways. Additional tools include analysis, visualization, and interpretation of 
data commonly performed using R, Python, or other programming languages. 
In this thesis, protein cleanup was performed using slightly modified filter-aided sample 
preparation (FASP) protocol (paper I/III/IV) or single-pot, solid-phase-enhanced sample-
preparation (SP3) protocol (paper II)120,121.  Proteins were digested into peptides using 
trypsin alone (paper I/III) or together with Lys-C (paper II/IV). Additional phospho-peptide 
enrichment step was performed in paper IV using TiO2 beads in phosphoproteomics 
samples. Peptides (paper I-III), or enriched phosphopeptides (paper IV) were labelled with 
TMT10plex isobaric label reagent. Labelled peptides were pooled together and  pre-
fractionated using HiRIEF fractionation method119 (paper I-IV). Proteomic and 
phosphoproteomic analysis by LC-MS/MS were performed using Q Exactive mass 
spectrometer (paper I-IV). DEqMS R package was used to perform differential protein 
expression analysis in paper II122. Pathway enrichment was performed using WebGestalt in 
paper II/IV123. 
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2.3 RESULTS AND DISCUSSION  
2.3.1 Paper I: microRNAs with AAGUGC seed motif constitute an integral 
part of an oncogenic signaling network  
It has been previously shown that miRNA dysregulation is involved in carcinogenesis and 
could be used to improve cancer therapy124,125. How miRNAs regulate cancer progression and 
the response to EGFR-TKI remains largely unknown. This paper was initiated based on the 
general interest towards the function of oncogenic miRNAs’ in NSCLC and in response to 
EGFR-TKIs in particular.  
The main findings in this paper include: 
• The identification of a group of miRNAs with the same AAGUGC motif (oncomotif) 
in their seed sequence that has an impact on cell proliferation and EGFR-TKI 
sensitivity. 
• Well-known tumor suppressors were identified and validated as miR-372-3p targets 
in the NSCLC cell line model.  
• High expression of miR-372-3p increased the sensitivity to EGFR-TKI in NSCLC 
cell lines.  
• The expression of oncomotif-miRNAs in lung ADC is associated with E2F driven 
cell proliferation, TP53 mutation, MYC amplification, and shorter relapse-free 
survival. 
• Oncomotif-miRNAs are part of the oncogenic signaling network in NSCLC and 
multiple other cancer types by regulating cancer cell proliferation through controlling 
their target tumor suppressors. 
The target analysis of miRNAs revealed that our suggested oncomotif-miRNAs regulate 
several previously reported tumor suppressors in various cancer types126–128. Notably, the 
selection of miR-372-3p targets investigated in this paper were chosen by the results 
provided by a miRNA target prediction algorithm together with a literature search of 
currenly known tumor suppressors. The miRNA target prediction algorithm may introduce 
false-positive and false-negative predictions, which when taken together with current tumor 
suppressor knowledge from the literature search could be a limiting factor by influencing 
our perspective on which miRNA are true as well as relevant for further investigation. 
Therefore, important miRNA targets that contribute to cell proliferation and EGFR-TKI 
sensitivity may still be among the false-negatives and hence unfortunately left 
uninvestigated. Nevertheless, since the miRNA targets that were identified and validated 
contained previously known tumor supressors, it would provide a relevant justification to 
investigate the clinical prevalence of our identified oncomotif-miRNAs in NSCLC patients, 
but perhaps improved diagnostic kits would have to be developed to achieve such a study.  
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2.3.2 Paper II: Immediate adaptation analysis implicates BCL6 as an EGFR-
TKI combination therapy target in NSCLC 
In paper I, oncomotif-miRNAs were shown to impact EGFR-TKI sensitivity, but miRNAs 
are not commonly used as drug targets. Instead, it is more common to target a protein. 
Previously, many studies were focusing on finding the proteins involved in intrinsic 
resistance or acquired resistance of EGFR-TKIs. However, rapid adaptative response to 
targeted therapies is equally interesting because it could be responsible for short-lived 
clinical response129. Immediate adaptative response to EGFR-TKI treatment is less reported 
in NSCLC. We therefore initiated the study of the immediate adaptive response to EGFR-
TKI treatment in NSCLC to identify and investigate the involved proteins, which in turn 
would also be anticipated potential drug targets in combination with EGFR-TKI treatment. 
The main findings in this paper include: 
• Short term EGFR-TKI treatment already results in dramatic changes in the cellular 
signaling as immediate adaptative response. 
• EGFR-TKI treatment results in the upregulation of BCL6, ERBB3, FGFR2, JAK3, 
which indicate a role for them in the immediate adaptive response and could be 
essential regulators in treatment escape. 
• The drug combination screen indicates that dual inhibition combinations of EGFR 
and FGFR2 or JAK3 are synergetic.  
• Dual targeting of BCL6 and EGFR results in increased apoptosis and synergistic cell 
killing in various NSCLC cell lines. 
The observation of BCL6, ERBB3, FGFR2, and JAK3 as critical components as immediate 
adaptive response to EGFR-TKI treatment in NSCLC is exciting, as some of the 
targets/pathways were previously reported to be TKI resistance mechanisms15,130–133. Our 
primary focus, BCL6, was reported as a drug resistance mechanism to the BCR-ABL1 
targeting TKI imatinib in leukemia cells130. The combination therapy targeting BCL6 and 
phosphor-STAT3 was suggested for NSCLC  treatment due to its ability to reduce tumor 
growth134. This was in line with our observation that BCL6 and JAK regulated STAT 
signaling contribute to EGFR-TKI treatment escape. 
Notably, there was a limitation in our initial observation of immediate adaptive response to 
EGFR-TKI treatment, as it was performed in the A431 cell line but not in an NSCLC cell 
line. Our rational for initially using A431 was based on its high expression level of EGFR and 
commonly used as a model system for EGFR signaling. However, this study was able to 
show in NSCLC cells that EGFR-TKI treatment resulted in significant increase in cell killing 
upon dual targeting of BCL6 and EGFR as opposed to targeting only either one of the 
proteins.  Thus, at least indicating that BCL6 in NSCLC cells may still contribute to survival 
and treatment escape following EGFR-TKI treatment. Another limitation regarded the 
selection of upregulated mRNAs and proteins to further explore, as this was partially based 
on the overlap between our profiling data and the COSMIC cancer gene census (CGC) data. 
Since the CGC does not cover all cancer related mutated genes, this added a bias in the 
selection of candidates to further explore. It is therefore important to note that transcripts and 
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proteins not present in the overlap between our profiling data and the CGC’s data, may still 
hold important roles in EGFR-TKI response. Furthermore, the work in this paper is 
performed using cell lines as model systems, but the heterogeneity of tumors and the toxicity 
of combination therapy could introduce more complexity to combination treatment. It is 
therefore recognized that further investigation would be needed in an in vivo and/or clinical 
setting to validate these findings.  
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2.3.3 Paper III: CDKN2A status predicts the response to EGFR targeting 
therapy in EGFRwt NSCLC 
Current approved EGFR-TKIs are limited and focused to treat NSCLC patients with EGFR 
mutations. For patients with wild type EGFR, only a subpopulation of them will benefit 
from EGFR-TKI treatment135,136. It is therefore desirable to be able to identify the 
subpopulation of NSCLC patients with wild type EGFR (EGFRwt) that could benefit from 
EGFR-TKI treatment136. No biomarker for estimating EGFR-TKI response in EGFRwt 
NSCLC is currently available, making it difficult for clinicians to decide the best treatment 
for the patients with EGFRwt. In this paper, we wanted to find novel biomarkers and drug 
targets for EGFR-TKI based combination therapy in EGFRwt NSCLC.  
The main findings in this paper include: 
• CDKN2A loss is associated with EGFR-TKI sensitivity in EGFRwt NSCLC. 
• Epithelial cell lineage is associated with EGFR-TKI sensitivity, and mesenchymal 
cell lineage is associated with resistance to EGFR-TKI in CDKN2A deleted EGFRwt 
NSCLC. 
• BCL2L1 (coding for BCL-xL) overexpression exist before EGFR-TKIs in EGFR-TKI 
responding cell lines. 
• EGFRwt, KRASwt, and CDKN2A deleted NSCLC is sensitive to BCL-xL and EGFR 
dual inhibition.  
CDKN2A encodes for both p16 and p14, where p16 regulates G1/S transition to control 
proliferation and p14 regulates p53 to control apoptosis137.  The cell lines in our study which 
were defined as molecular responders, all harbor CDKN2A deletion and are sensitive to 
EGFR-TKIs. Considering that CDKN2A deletion is frequently detected in 13.9% of ADC and 
27% of SQCC (Table 1), the finding in this paper has the potential to better select patients 
who can benefit from EGFR-TKIs.  
The limitations of this study include:  
• CDKN2A loss as a biomarker requires further validation in vivo and clinical settings.  
• Currently, all the BCL-xL targeting drugs are still under investigation, limiting our 
understanding of their suitability and toxicity in a clinical setting. 
  
  23 
2.3.4 Paper IV: Integrative proteomics and phosphoproteomics profiling of 
NSCLC cell lines to explore osimertinib resistance mechanisms 
Paper I-III studied the response or resistance mechanisms using first-generation of EGFR-
TKIs. Recently, the third-generation of EGFR-TKI osimertinib received quick approval from 
FDA to be used as first-line treatment. However, tumors change and develop new resistance 
mechanisms also to third-generation of EGFR-TKIs. In this study we investigated the 
osimertinib resistance mechanisms using osimertinib resistant NSCLC cell models.  
The main findings in this paper include: 
• Identification of upregulation of AXL and its ligand GAS6, and EMT as potentioal 
resistance mechanisms to osimertinib by proteomics profiling 
• Identification of reactivation of MAPK pathway, and AXL dependent CDK1 
phosphorylation as potential resistance mechanisms to osimertinib by 
phosphoproteomics profiling 
• A proteomic and phosphoproteomic profiling data resource of osimertinib resistant 
cell line models for further investigation 
The osimertinib resistance mechanisms identified via our -omics profiling have been 
previously reported by others, which indicate that our -omics approach identified relevant 
resistance mechanisms. For instance, the upregulation of AXL and GAS6 were reported in 
various studies as a resistance mechanisms to first-generation of EGFR-TKIs or 
osimertinib90,111,138. Moreover, Kim and colleagues recently reported that the degradation of 
AXL and EGFR-TKI treatment overcame the acquired resistance in NSCLC139.  
Constraints in time and funding led us to only initiate a minor pilot investigation. The 
proteomic and phosphoproteomic profiling was performed only with duplicate samples, 
which limited the statistical analysis. Consequently, the suggested resistance mechanisms to 
osimertinib in this paper require further validatory experiments with more replicates and 
statistical evaluation.  
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2.4 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVE 
The work presented in this thesis aimed at better understanding response and resistance 
mechanisms to EGFR-TKIs in NSCLC and to find novel biomarkers as well as drug targets 
or combination therapies for NSCLC. This has been achieved and summarized with this 
thesis. 
Presence of cancer specific miRNA fingerprints were identified in various cancers 
including lung cancer140–142. miR-373 and miR-520c have been observed to be metastasis 
promoting miRNAs in breast cancer cells143.  In lung cancer, the overexpression of miR-17-
92 cluster was observed to enhance cell proliferation144. Paper I described onco-motif 
miRNAs as part of oncogenic signaling in NSCLC and other types of cancers, which 
included miR-372 that is a member of the miR-371-373 cluster located on chromosome 
19q13. This type of study led us to further understand NSCLC cellular signaling in 
response to EGFR-TKI.  Moreover, it would be interesting to explore in NSCLC patients 
the prevalence of the oncomotif-miRNAs that we identified and the subsequent application 
of these oncomotif-miRNAs as a predictive biomarker for sensitivity to EGFR-TKI 
treatment.  
A natural question that arises then is how well miRNAs can be detected in patients. 
Previously, Weber and colleagues reported that the miRNAs were detected in 12 biological 
fluids, which included serum, plasma, saliva, and urine145. Later on Roa and colleagues 
reported the high sensitivity and specificity of detecting miRNA panel in NSCLC patients 
using quantitative real-time polymerase chain reaction (RT-qPCR)) to analyze patient 
sputum146. It is therefore conceivable that miRNAs could be clinically used as biomarkers 
to determine which EGFR-TKI treatment is suitable for a given NSCLC patient. Especially 
since using body fluid is much less invasive than using tissue biopsy (easier sampling for 
NSCLC patients) and RT-qPCR is already widely used in hospitals (easy and cost-effective 
detection method).  
When we observed the upregulation of BCL6, ERBB3, FGFR2, and JAK3 in our molecular 
profiling in response to EGFR-TKIs in Paper II, we also noticed that three out of four were 
protein kinases. Protein kinases are widely used as drug targets because their function is 
frequently altered in cancer associated signaling transduction networks and 48 protein 
kinase inhibitor drugs have been approved by FDA, 35 of which are TKIs147. Therefore, the 
three protein kinases that we identified could be proposed as targets for EGFR-TKI drug 
combination for NSCLC treatment.  
Previous studies revealed that protein kinases ERBB3 and FGFR2 were associated to 
EGFR-TKI resistance in NSCLC15,131. Dual targeting of EGFR and ERBB3 was shown to 
overcome the acquired resistance to EGFR-TKIs148. A more recent study observed EGFR 
and ERBB3 expression in circulating tumor cells and tumor tissues from NSCLC patients, 
which made the ERBB3 driven resistance to NSCLC more easily diagnosed149.  There are, 
however, no currently ERBB3 targeting drugs approved by FDA. Our drug combination 
therapy screen data showed a multi-targeting drug nintedanib (Vargatef®) targeting 
FGFR1-3 that is synergistic with EGFR-TKIs. In EU it is approved for treating advanced 
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lung ADC patients. However, it is not currently approved as a combination therapy together 
with an EGFR-TKI. Although, this would be an interesting avenue to explore. 
Upregulation of JAK3 was only observed in our mRNA level molecular profiling but the 
inhibition of JAK by multi-kinase targeting drug momelotinib together with EGFR-TKI 
was shown to be synergistic in our drug combination therapy screen. The investigation of 
JAK members and their relation to EGFR-TKI resistance in NSCLC mainly focused on 
JAK1/2, since JAK2 inhibition was previously shown to restore EGFR-TKI sensitivity in 
EGFR-TKI resistant NSCLC in both cell lines and xenograft models150. The combination of 
an approved JAK1/2 inhibitor ruxolitinib (Jakafi®) with first-generation EGFR-TKI 
erlotinib has already been investigated in a clinical trial, but the patients’ response to this 
combination were poor. Another clinical trial of osimertinib and ruxolitinib combination 
was planned, according to Yu and colleagues151. The role of JAK3 in resistance 
mechanisms of EGFR-TKI in NSCLC remains unclear, but likely would be relying on 
JAK-STAT signaling, hence inhibitors of this pathway could be used to further investigate 
this resistance mechanism. As a potential JAK3 inhibitor, momelotinib recently received 
FDA fast track designation for targeting JAK1/2, but is not yet approved. Its JAK3 
inhibition ability was reported by Selleckchem with cell-free assay although the selectivity 
to JAK3 compared with JAK1/2 was weaker. Momelotinib showed synergistic effect 
together with EGFR-TKIs in our drug screen data. It would be interesting to continue to 
study JAK3 and EGFR inhibitor combination in NSCLC with JAK3 specific inhibitors 
instead of momelotinib, which target JAK1-3.  
BCL6 has not been previously associated with EGFR-TKI response in NSCLC, but BCL6 
and STAT3 inhibitor combination was previously reported to inhibit cell growth in NSCLC 
cell lines and xenografted tumor134. Notably, the combination of BCL6 inhibitor RI-BPI 
and imatinib (BCR-ABL1 TKI drug) has synergistic effects to rapidly induce cell death in 
cancer cells and promote longer survival for host mice in a xenograft model130. However, 
the dual targeting of EGFR and BCL6 in NSCLC have not previously been reported. In 
Paper II we observed that NSCLC cell sensitivity to EGFR-TKI is increased when BCL6 
is also inhibited and hence this would be an interesting combination therapy to evaluate. 
CDKN2A homozygous deletion was observed in 29% of the lung SQCC cases31. BCL2 or 
BCL-xL reactivation was observed in EGFR mutated NSCLC cell line with TKI resistance 
and 152.  No report has previously associated CDKN2A deletion as a biomarker for EGFR-
TKI sensitivity in NSCLC with wild type EGFR, hence in Paper III we were excited to 
have observed such a connection. From this observation, we suggested CDKN2A loss as a 
biomarker to predict EGFR-TKI sensitivity and proposed BCL-xL as a target for EGFR-
TKI combination therapy in EGFRwt CDKN2A deletion NSCLC.   
Due to limitations in time and available materials, we could only observe but not yet fully 
validate several potential osimertinib resistance mechanisms in Paper IV. The potential 
resistance mechanisms observed were via the upregulation of AXL or its ligand GAS6, 
MAPK pathway reactivation, and AXL dependent CDK1 phosphorylation. Further 
validatory experiments with more replicates could generate better insight into which 
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potential resistance mechanisms would be worth targeting as a means to improve EGFR-
TKI treatment.  
The recommendations for future research from the work presented in this thesis can be 
summarized as follows: 
• Finding and validating an efficient method to detect oncomotif-miRNAs from body 
fluids or tumor tissue and test the oncogmotif-miRNAs’ potential to be used as a 
biomarker for selecting patients for targeted therapy.   
• Validating the potential of dual targeting BCL6 and EGFR as a combination therapy 
in NSCLC  
• Validating CDKN2A deletion as a biomarker for predicting EGFR-TKI sensitivity in 
EGFRwt NSCLC related clinical setting. 
• Validating BCL-xL inhibitor and EGFR-TKI combination therapy in EGFRwt 
CDKN2Adel NSCLC.  
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